NEW YORK--(BUSINESS WIRE)--First graph, third sentence of release should read: IntelliCell’s notable Advisory Board additions include: James R. Andrews, M.D.; Joshua Hackel, M.D.; Jeffrey R. Dugas, M.D.; Kevin Wilk, of the Andrews of Orthopedic and Sports Medicine; Frederic Nicola, MD from D.I.S.C. Sports & Spine Center, who is the team doctor for the Oakland Raiders. (sted IntelliCell’s notable Advisory Board additions include: James R. Andrews, M.D.; Joshua Hackel, M.D.; Jeffrey R. Dugas, M.D.; Kevin Wilk, M.D. of the Andrews of Orthopedic and Sports Medicine; Frederic Nicola, MD from D.I.S.C. Sports & Spine Center, who is the team doctor for the Oakland Raiders and Los Angeles Kings.)
The corrected release reads:
INTELLICELL BIOSCIENCES INC. ANNOUNCES THE ADDITION OF WORLD RENOWNED ORTHOPEDIC SURGEONS AND SPORTS MEDICINE DOCTORS TO MEDICAL ADVISORY BOARD
Company believes the market for non-enzymatic stromal vascular therapy for the professional sports medicine market is in excess of $1 Billion
IntelliCell Biosciences, Inc. (OTCQB: SVFC.PK) welcomes five world-renowned orthopedic surgeons and sports medicine doctors to their esteemed Medical Advisory Board. Poised to help physicians change the way sports injuries are treated, IntelliCell has partnered with the nation’s top medical leaders to bring their proprietary non-enzymatic process for the production of Stromal Vascular Fraction (SVF) from autologous adipose tissue to the market. IntelliCell’s notable Advisory Board additions include: James R. Andrews, M.D.; Joshua Hackel, M.D.; Jeffrey R. Dugas, M.D.; Kevin Wilk, of the Andrews of Orthopedic and Sports Medicine; Frederic Nicola, MD from D.I.S.C. Sports & Spine Center, who is the team doctor for the Oakland Raiders.
“We are extremely excited to have several of the top opinion leaders in sports medicine join our Advisory Board,” said Dr. Steven Victor, Chairman of IntelliCell Biosciences. “We are assembling a blue-chip team that will help us to better understand how SVF will benefit professional athletes across the world of sports.”
Recently, doctors using SVF cells manufactured through IntelliCell’s proprietary non-enzymatic process have successfully treated several professional athletes with outstanding results. By partnering with prestigious sports medicine doctors, IntelliCell executives believe that IntelliCell’s SVF cell therapy will benefit professional athletes in the rehabilitation and prevention of sports injuries, thus elongating players’ careers.
Dr. Andrews, of the Andrews Institute of Orthopedic and Sports Medicine in Gulf Breeze, FL, is internationally known for his scientific and clinical research contributions in knee, shoulder and elbow injuries, in addition to his skill as an orthopedic surgeon. A member of both the American Board of Orthopedic Surgeons and the American Academy of Orthopedic Surgeons, Dr. Andrews also serves as Senior Orthopedic Consultant for the Washington Redskins and Medical Director for the Tampa Bay Rays.
“I am dramatically impressed with IntelliCell’s proprietary non-enzymatic method for manufacturing Stromal Vascular Fraction from a person’s own adipose tissue,” said Dr. Andrews. “The amount of SVF cells that this process creates will enable physicians to treat sports injuries without the need for culturing the cells or adding enzymes. We are looking forward to employing this process at our own Institute and to conduct further research with the IntelliCell team on this exciting regenerative medicine.”
Other Partners of the Andrews Institute joining IntelliCell’s leadership team are Dr. Hackel, of the Pensacola office, and Dr. Dugas and Dr. Wilk, of the Birmingham, Alabama office. Serving on the Board of Trustees at ASMI and the American Baseball Foundation, Dr. Dugas remarked, “We look forward to utilizing IntelliCell in the treatment of our patients. The results of SVF-use to reduce inflammation are well-known, but IntelliCell’s procedure allows us to treat patients without the use of chemicals. This is a major step forward in treating injured athletes.”
Team Physician for the Oakland/Los Angeles Raiders since 1983, Dr. Nicola echoes Andrews Institute’s sentiments: “I am beyond impressed with IntelliCell’s innovative technology. The idea of getting anywhere between .5-1billion SVF cells, which are mostly stem cells from 60cc’s of adipose tissue, is remarkable. Until IntelliCell came along, chemicals were needed to break apart the adipose tissue. I believe this is a huge breakthrough for the majority of sports-related injuries.”
About IntelliCell Biosciences, Inc.
IntelliCell is a pioneering regenerative medicine company focused on the expanding regenerative medical markets using stromal vascular fraction derived from adult adipose tissue. IntelliCell intends to initially focus on setting up tissue processing centers throughout the United States with managing partners. The centers will receive and employ the IntelliCell™ process to the adipose stromal vascular fraction harvested by physicians in their own offices, and then return the IntelliCells™ to the physicians the same day labeled "autologous homologous." IntelliCell has already established processing centers in New York City, Philadelphia, Dallas/Ft. Worth, and New Orleans, and has entered into a licensing agreement for a center in Palm Beach. In the future, IntelliCell intends to pursue expansion to secondary markets and beyond the U.S. through a combination of company-owned and licensed clinical facilities. For additional information, visit http://www.intellicellbiosciences.com or call 212-249-3050.